Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nasus Pharma (NSRX) presented Phase 2 data showing NS002 reached a therapeutic epinephrine threshold faster than an autoinjector. The NP007 study evaluated the investigational nasal powder for anaphylaxis, a severe allergic reaction. NS002 reached the 100 pg/mL threshold sooner after both single and repeat dosing. Results also showed potential superiority over the autoinjector under severe nasal congestion. No serious adverse events were observed.
The findings were presented at the ACAAI 2026 Annual Scientific Meeting, held November 12–16 in Phoenix. Nasus plans to initiate a pivotal study in the fourth quarter of 2026, with topline results expected in the first quarter of 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointNS002 reached the 100 pg/mL threshold faster than an autoinjector after single and repeat dosing.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Nasus plans a fourth-quarter 2026 pivotal study start, with topline results expected in first-quarter 2027.
- Minor pointNS002 showed potential superiority over the autoinjector under severe nasal congestion.
- Minor pointNP007 recorded no serious adverse events.
Negative
- None.
Key Figures
- Therapeutic threshold
- 100 pg/mL
- NS002 reached the threshold sooner than an autoinjector after single and repeat dosing
- Pivotal study initiation
- Before the end of 2026
- Planned NS002 pivotal study
- Topline data readout
- First quarter of 2027
- Planned NS002 readout
Historical Context
-
FDA cleared the NS002 study; prior Phase 2 data showed faster threshold attainment than EpiPen.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
intranasal medical
anaphylaxis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive Data Validate the Potential of NS002 in the Treatment of Anaphylaxis as Company Prepares to Initiate Pivotal Study in the Fourth Quarter of 2026
TEL AVIV, Israel, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced highlights of positive data presented at the American College of Allergy, Asthma and Immunology (“ACAAI”) 2026 Annual Scientific Meeting, held November 12-16 in Phoenix, Arizona. Results from the Company’s NP007 trial, a Phase 2 study of NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis, were selected for oral presentation in the “Distinguish Industry and Late Breaking Abstracts” session and as posters during the conference. Additional survey results of U.S. allergists on the importance of speed of onset in anaphylaxis were also presented.
The data presented at the ACAAI highlighted results from the NP007 study, which demonstrated that NS002 achieved faster time to therapeutic threshold as compared to an autoinjector. NS002 reached the 100 pg/mL threshold sooner than the autoinjector after both single and repeat dosing. Potential superiority was also demonstrated against the autoinjector in conditions of severe nasal congestion. No serious adverse events were observed. Additional survey data of U.S. allergists showed that prescribers emphasize speed of onset and the proportion of patients reaching the therapeutic level within the first minutes as meaningful differences when considering therapeutic options.
“We believe the data presented to the allergy and immunology community at ACAAI represent an important validation of NS002 and the potential of our Nasax® platform,” said Brendan O’Grady, Chief Executive Officer of Nasus Pharma. “We are encouraged by these results, and confident in the program as we prepare to initiate the NS002 pivotal study before the end of 2026 and a topline data readout in the first quarter of 2027.”
Detailed results and presentations are available on the ACAAI website.
About Nasus Pharma Ltd.
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus Pharma’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus Pharma’s proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nasus Pharma is using forward-looking statements in this press release when it discusses: the belief that the presentations made at ACAAI validate NS002 and demonstrate the potential of the Nasax® platform; the anticipated initiation of the NS002 pivotal study before the end of 2026; and the anticipation of the topline data readout in the first quarter of 2027. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 25, 2026. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Corporate Contact
Nasus Pharma Ltd. Israel
info@nasuspharma.com
Investors Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.